IMMUNOME INC (IMNM) competitors & alternatives
Health Care · NASDAQ
IMMUNOME INC (IMNM)'s top competitors and alternatives — its most similar public companies — include SUTRO BIOPHARMA INC (STRO), Pfizer (PFE), ARRIVENT BIOPHARMA INC (AVBP), CRESCENT BIOPHARMA INC (CBIO), ZYMEWORKS INC (ZYME), ADC THERAPEUTICS SA (ADCT), WHITEHAWK THERAPEUTICS INC (WHWK), Pyxis Oncology, Inc. (PYXS), CYTOMX THERAPEUTICS INC (CTMX), CORBUS PHARMACEUTICALS HOLDINGS IN (CRBP), Exelixis (EXEL) and NURIX THERAPEUTICS INC (NRIX). These are IMMUNOME INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top IMNM competitors & alternatives
-
SUTRO BIOPHARMA INCSTROHealth Care
Sutro Biopharma is a clinical-stage oncology firm using proprietary cell-free protein synthesis technology to develop specialized antibody-drug conjugates for…
$23.40 (as of 2026-07-22) · market cap $388M
-
PfizerPFEHealth Care
Global biopharmaceutical company discovering, developing, and manufacturing prescription medicines and vaccines across oncology, immunology, cardiovascular,…
$24.82 (as of 2026-07-22) · market cap $142.0B
-
ARRIVENT BIOPHARMA INCAVBPHealth Care
Arrivent Biopharma is a clinical-stage oncology company advancing firmonertinib, an EGFR-targeted tyrosine kinase inhibitor for treating non-small cell lung…
$30.44 (as of 2026-07-22) · market cap $1.3B
-
CRESCENT BIOPHARMA INCCBIOHealth Care
Crescent Biopharma is a clinical-stage oncology company developing a novel PD-1 x VEGF bispecific antibody and a portfolio of antibody-drug conjugates to…
$15.83 (as of 2026-07-22) · market cap $615M
-
ZYMEWORKS INCZYMEHealth Care
A biotech company pioneering multispecific antibodies and ADCs for cancer and autoimmune disease, monetizing through a partnership-driven royalty aggregation…
$23.36 (as of 2026-07-22) · market cap $1.7B
-
ADC THERAPEUTICS SAADCTHealth Care
ADC Therapeutics develops antibody-drug conjugates (ADCs) targeting hematologic and solid tumors, with its lead product ZYNLONTA commercialized for lymphoma.
$1.24 (as of 2026-07-22) · market cap $158M
-
WHITEHAWK THERAPEUTICS INCWHWKHealth Care
Clinical-stage oncology company developing next-generation antibody-drug conjugates (ADCs) targeting validated tumor antigens with advanced linker-payload…
$3.99 (as of 2026-07-22) · market cap $216M
-
Pyxis Oncology, Inc.PYXSHealth Care
Pyxis Oncology is a clinical-stage biopharma developing innovative antibody-drug conjugates (ADCs) that target the tumor microenvironment to improve efficacy…
$2.53 (as of 2026-07-22) · market cap $160M
-
CYTOMX THERAPEUTICS INCCTMXHealth Care
CytomX is developing conditionally activated cancer therapies using its PROBODY platform to enable selective tumor targeting with reduced systemic toxicity,…
$3.33 (as of 2026-07-22) · market cap $724M
-
CORBUS PHARMACEUTICALS HOLDINGS INCRBPHealth Care
Clinical-stage biopharmaceutical company developing next-generation antibody drug conjugates for oncology and a CB1 receptor inverse agonist for obesity.
$8.84 (as of 2026-07-22) · market cap $163M
-
ExelixisEXELHealth Care
Exelixis is a profitable oncology company commercializing the multi-kinase inhibitor cabozantinib across multiple cancer indications while advancing a pipeline…
$54.98 (as of 2026-07-22) · market cap $14.0B
-
NURIX THERAPEUTICS INCNRIXHealth Care
Clinical-stage biotech pioneering AI-powered targeted protein degradation medicines for cancer and autoimmune diseases, with Phase 2 lead candidate…
$23.60 (as of 2026-07-22) · market cap $2.4B
Not quite? Describe exactly what you want →
Peers are IMMUNOME INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: IMMUNOME INC (IMNM).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.